Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 35, Issue 8, Pages 384-396Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2014.05.004
Keywords
pharmacoepigenetics; DNA methylation; 5-hydroxymethylcytosine; histone modifications; epidrugs; epigenetic editing
Categories
Funding
- The Swedish Research Council
- Swedish Cancer Fund
- FP-7/Seurat 1 project NOTOX
- IMI-JU project MIP-DILI
- Marie Curie [CIG 322283]
Ask authors/readers for more resources
There are pronounced interindividual variations in drug metabolism, drug responses, and the incidence of adverse drug reactions. To a certain extent such variability can be explained by genetic factors, but epigenetic modifications, which are relatively scarcely described so far, also contribute. It is known that a novel class of drugs termed epidrugs intervene in the epigenetic control of gene expression, and many of these are now in clinical trials for disease treatment. In addition, disease prognosis and drug treatment success can be monitored using epigenetic biomarkers. Here we review these novel aspects in pharmacology and address intriguing future opportunities for gene-specific epigenetic editing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available